Company profile for Synthekine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders. We are discovering and developing engineered derivatives of therapeutically relevant, naturally occurring cytokine...
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders. We are discovering and developing engineered derivatives of therapeutically relevant, naturally occurring cytokines. These carefully engineered proteins provide tunable agonism of cytokine signaling while minimizing undesired activities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1505 O'Brien Drive Menlo Park, California 94025
Telephone
Telephone
650.271.9888
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251113131381/en/First-Patient-Dosed-in-SYNERGY-101-a-Global-Randomized-Phase-2-Clinical-Trial-of-STK-012-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251107945337/en/Synthekine-Presents-Positive-Initial-Results-from-Phase-1a1b-Clinical-Trial-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

BUSINESSWIRE
07 Nov 2025

https://www.businesswire.com/news/home/20251030999592/en/Synthekine-Announces-Late-Breaking-Oral-Presentation-of-Initial-Clinical-Data-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-NSCLC-at-SITC-2025-Annual-Meeting

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20241209042495/en

BUSINESSWIRE
09 Dec 2024

https://www.businesswire.com/news/home/20241108163003/en

BUSINESSWIRE
08 Nov 2024

https://www.businesswire.com/news/home/20240904876543/en

BUSINESSWIRE
04 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty